Janssen Pharmaceuticals NV has joined the Structural Genomics Consortium’s (SGC) group to partner in the investigation of epigenetics-based drug research, a new and burgeoning field in the development of future medicines.
One of the largest ever early-stage research partnerships between the pharmaceutical industry and the public sector, the SGC receives its core funding through Genome Canada, the Ontario government and the Wellcome Trust. The SGC is based at the Universities of Oxford and Toronto, with funding and research activities split between the two sites.
The SGC’s mandate is to identify and map the 3-D structure of human proteins and use this information to generate research tools to enable drug discovery. Its work is important in helping scientists better understand the role of human proteins in disease. All SGC research output of target protein and probe compounds is placed into the public domain, without restriction on use .
In the field of epigenetics, the SGC and its research network of 200 scientists are focused on facilitating the discovery, validation and development of new treatments in this cutting-edge research area.
“We at SGC applaud the government of Canada for its recent successful free-trade negotiations with Europe, Comprehensive Economic and Trade Agreement (CETA), and the components within that agreement that reinforce the importance of life sciences research here in Canada and set the stage for more investment into research partnerships between the public and private sectors,” said Aled Edwards, chief executive, SGC.
Date: October 25, 2013
Source: Structural Genomics Consortium